China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7
You may also be interested in...
SFDA Proposes New Review Channel For Innovative Drugs
Pressured by increasing calls from industry, China’s State FDA released a new proposal to expedite new drug reviews, focusing on drugs with high clinical value.
Outlier: Takeda Scores Chinese Clinical Trial Authorization For Diabetes Agent In Record 7 Months
It’s not an anticancer therapy, and it has only Phase II data from overseas, but Takeda has managed to cut the average clinical trial authorization time for Class 1 new drugs in China by two months.
Lost In Reimbursement? Innovative Drugs Encounter Lengthy Delays In China – IMS Study
A market access study conducted by IMS and RDPAC sheds lights on regulatory and reimbursement challenges facing MNCs in China.